NUVB catalyst calendar

Nuvation Bio Inc.

Upcoming catalysts
8
Cash runway
Cash generating
Cash & investments
$661M
Phase 3 programs
4

Nuvation Bio Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 15, 2026, a projected date rather than a confirmed one. There are 8 upcoming events on record.

Nuvation Bio Inc. generates cash from operations, so a burn-based runway figure does not apply.

Across 9 concluded trials, 44% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 est. Next quarterly earnings (projected) Earnings —
February 2, 2027 Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib Trial Milestone Phase 1
March 15, 2027 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Trial Milestone Phase 1/Phase 2
December 1, 2028 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Trial Milestone Phase 3
January 15, 2029 A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Trial Milestone Phase 3
May 15, 2029 Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Trial Milestone Phase 3
August 30, 2030 Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) Trial Milestone Phase 3
September 15, 2030 Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Trial Milestone Phase 2

Track NUVB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open NUVB in the tracker

Recent history

DateEventTypePhase
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 6, 2026 8-K filed: Other event Filing —
June 30, 2026 8-K filed: Material agreement, Other event Corporate —
May 4, 2026 Quarterly results filed (8-K) Earnings —
March 2, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 Quarterly results filed (8-K) Earnings —
November 26, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 17, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 3, 2025 Quarterly results filed (8-K) Earnings —
August 7, 2025 Quarterly results filed (8-K) Earnings —
June 11, 2025 8-K filed: Reg FD disclosure, Other event Filing —
June 11, 2025 Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Trial Milestone Phase 2
May 7, 2025 Quarterly results filed (8-K) Earnings —
December 6, 2024 Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion Trial Milestone Phase 2
July 15, 2024 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Trial Milestone Phase 1
June 7, 2024 A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene Trial Milestone Phase 2
January 20, 2023 Study the Effect of Omeprazole on AB-106 Pharmacokinetics Trial Milestone Phase 1
August 31, 2022 Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors Trial Milestone Phase 1
December 3, 2021 A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK Trial Milestone Phase 1
August 20, 2021 A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin Trial Milestone Phase 1
March 15, 2019 A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.